Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBS 001

Next Previous
Drug Profile

CBS 001

Alternative Names: Anti-LIGHT monoclonal antibody - Centessa Pharmaceuticals; Anti-TNFSF14-monoclonal-antibody - Centessa Pharmaceuticals; CBS-001

Latest Information Update: 26 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Capella BioScience
  • Developer Capella BioScience; Centessa Pharmaceuticals
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Tumour necrosis factor ligand superfamily member 14 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Idiopathic pulmonary fibrosis; Inflammation

Most Recent Events

  • 24 Jun 2026 Centessa Pharmaceuticals has been acquired by Eli Lilly and Company
  • 22 Aug 2023 Capella Bioscience and Centessa Pharmaceuticals terminate a phase I trial in Inflammation (In volunteers) in United Kingdom (IV), due to portfolio reprioritisation (NCT05323110)
  • 30 Mar 2023 Suspended - Phase-I for Idiopathic pulmonary fibrosis (In volunteers) in United Kingdom (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top